Genus H1 2026 slides: record profit despite flat revenue, China deal
#Genus PLC #H1 2026 results #record profit growth #China joint venture #PRRS-resistant pig technology #animal genetics #London Stock Exchange #royalty business model
📌 Key Takeaways
- Genus PLC reported record profit growth of 57% despite flat revenue in H1 2026
- Shares fell 8.99% amid investor concerns about sustainability of margin expansion
- Strategic joint venture with Beijing Capital Agribusiness in China delivered £5.6m milestone payment
- Canadian approval secured for PRRS-resistant pig technology with approvals in seven countries total
📖 Full Retelling
Genus PLC (LON:GNS) announced record profit growth of 57% in its interim results for the first half of fiscal year 2026 on February 26, 2026, despite flat revenue, while shares tumbled 8.99% as investors expressed concerns about underlying market conditions and the sustainability of margin expansion, with CEO Jorgen Kokke and CFO Andy Russell highlighting a transformative joint venture in China and continued regulatory approvals for the company's gene-edited PRRS-resistant pig technology. The animal genetics company delivered exceptional financial performance across key metrics, with adjusted profit before tax surging to £55.7m from £35.4m in the prior year period, while adjusted earnings per share climbed 53% to 60.8p, maintaining a solid balance sheet with adjusted leverage declining to 1.4x from 1.5x. Revenue remained flat at £335.6m, but the company's focus on operational efficiency and its transition toward higher-margin royalty revenues drove substantial bottom-line improvement, with both primary divisions delivering robust profit growth—particularly the porcine genetics business which saw royalty revenue grow 6% to £92.8m and adjusted operating profit surge 30% to £71.9m. The strategic joint venture with Beijing Capital Agribusiness, a leading state-backed agribusiness, created what management describes as 'the best platform to accelerate the long-term growth opportunity for PIC China,' resulting in a £5.6m milestone payment already received and approximately £100m expected in the fourth quarter of fiscal 2026, while the company also achieved another significant regulatory milestone with Canadian approval of its PRRS-resistant pig technology in January 2026, addressing Porcine Reproductive and Respiratory Syndrome that costs the global pork industry billions annually.
🏷️ Themes
Financial Performance, Strategic Partnerships, Regulatory Progress
📚 Related People & Topics
London Stock Exchange
Stock exchange in the City of London
The London Stock Exchange (LSE) is a global stock exchange based in Paternoster Square in the City of London, England. Founded in 1801, it is one of the world's oldest continuously operating stock exchanges. As of mid-2025, the exchange had a total market capitalisation of approximately US$5.9 trill...
Entity Intersection Graph
Connections for London Stock Exchange:
🏢
Share repurchase
5 shared
🏢
UBS
2 shared
🌐
Corporate finance
2 shared
🌐
SJP
1 shared
🏢
Bank of England
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold just higher ahead of U.S.-Iran nuclear talks Nvidia shares edge up as cash return questions remain despite revenue outlook beat Nvidia, Salesforce earnings; U.S.-Iran nuclear talks - what’s moving markets Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound (South Africa Philippines Nigeria) Genus H1 2026 slides: record profit despite flat revenue, China deal By Investing.com Company News Published 02/26/2026, 05:16 AM Genus H1 2026 slides: record profit despite flat revenue, China deal 0 GNS -10.09% Introduction & Market Context Genus PLC (LON:GNS) presented its interim results for the first half of fiscal year 2026 on February 26, revealing a striking divergence between operational performance and market sentiment. The animal genetics company reported record profit growth of 57% despite flat revenue, yet shares tumbled 8.99% to close at £2,885, reflecting investor concerns about underlying market conditions and the sustainability of margin expansion. The presentation, delivered by CEO Jorgen Kokke and CFO Andy Russell, emphasized substantial strategic progress including a transformative joint venture in China and continued regulatory approvals for the company’s gene-edited PRRS-resistant pig technology. Financial Performance Highlights Genus delivered exceptional profit growth in the six months ended December 31, 2025, demonstrating the leverage inherent in its high-margin royalty business model. The company’s financial performance showed significant improvement across key metrics despite challenging market conditions. Adjusted profit before tax surged to £55.7m from £35.4m in the prior year period, while adjusted earnings per share climbed 53% to 60.8p. The company maintained a solid balance sheet with adjusted leverage declining to 1.4x from 1.5x, while return on invested capital improved to 15.8% from 14.7%. Revenue remained flat at £335.6m, but the company’s focus on o...
Read full article at source